Triglav Skladi’s BioMarin Pharmaceuticals BMRN Stock Holding History

Triglav Skladi’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$944K	Hold	16,500	–	–	0.05%	140
2026 Q1	$932K	Hold	16,500	–	–	0.07%	129
2025 Q4	$981K	Hold	16,500	–	–	0.06%	132
2025 Q3	$894K	Hold	16,500	–	–	0.06%	119
2025 Q2	$907K	Hold	16,500	–	–	0.07%	111
2025 Q1	$1.17M	Hold	16,500	–	–	0.1%	96
2024 Q4	$1.08M	Buy	+16,500	New	+$1.11M	0.09%	100

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Triglav Skladi's BMRN Position: Q2 2026 in Review

Triglav Skladi held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 16,500 shares worth $944K. The position accounts for 0.05% of the portfolio, ranked #140.

Triglav Skladi first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.17M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Triglav Skladi held 16,500 shares of BioMarin Pharmaceuticals worth $944K as of Q2 2026.
Triglav Skladi left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.05% of Triglav Skladi's portfolio in Q2 2026, its #140 holding.
Triglav Skladi first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Triglav Skladi's BioMarin Pharmaceuticals position peaked at $1.17M in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Triglav Skladi's 13F filing for Q2 2026, filed 11 Aug 2026.